InvestSMART

Adherium Limited (ASX:ADR)

ALERT: Price-sensitive ASX Announcement for ADR
Current share price for ADR : $0.100 -0.005 (-4.76%)+
Announcement
Release
29 Jul 2026 8:29AM
Price at Release
$0.105
Full Release
download
Summary
Adherium Limited reported its Appendix 4C Quarterly Cash Flow for the quarter ending 30 June 2026. The company experienced significant growth in its Remote Patient Monitoring (RPM) subscription revenue, totaling A$479k, marking a 39% increase from the previous quarter. Customer receipts were A$408k, a substantial rise from the previous quarter. Operating cash outflows included staff costs of A$2,093k and administration costs of A$1,928k. Notably, Adherium's RPM devices and activations continued to expand, with the company aiming to reach approximately 10,000 device shipments by the end of 2026. Strategic efforts are focused on expanding RPM services and leveraging favorable reimbursement changes in the U.S. to support market growth. The quarter also saw significant strides in clinical validation, evidenced by the iCARE study results presented at the American Thoracic Society Conference.
Key Points
  • Adherium's RPM revenue grew 39% to A$479k.
  • Customer receipts increased to A$408k.
  • Staff costs were A$2,093k and admin costs A$1,928k.
  • Focus on expanding RPM and leveraging U.S. reimbursement changes.
  • iCARE study results showed significant healthcare cost reductions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.